Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartwatch help cancer patients during chemo and radiation?

NCT ID NCT05937659

Knowledge-focused Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 4 times

Summary

This study will test whether cancer patients receiving chemotherapy and radiation therapy can use wearable health devices, like fitness trackers, to monitor their heart rate and activity levels. Twenty adults will wear the device during treatment and for four weeks after, uploading data at clinic visits. The goal is to see if this is practical in a busy clinic and if the data helps doctors provide better supportive care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
wearable health technology device
What this could lead to
If successful, this could show that wearable devices help doctors spot early signs of health decline in cancer patients during treatment, leading to better supportive care.
What could go wrong
This is a very small, early feasibility study with only 20 people. It focuses on whether patients can use the technology, not on improving outcomes. The results may not apply to all cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult subjects were diagnosed with cancer and prescribed concurrent systemic therapy and radiation therapy and their providers.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria In order to participate in this study a subject must meet all of the eligibility criteria outlined below. Subjects 1. All genders aged ≥ 18 years of age. 2. English-speakers 3. Able to understand and cooperate with study procedures. 4. Signed and dated informed consent. 5. Subjects being seen at Novant-New Hanover Regional Medical Center for diagnosis and management of cancer. 6. Subjects prescribed to receive concurrent radiation therapy and systemic therapy either definitively or postoperatively. 7. Signed and dated HIPAA authorization for the release of personal health information. Providers 1. All genders aged ≥ 18 years of age. 2. English speakers. 3. Able to understand and cooperate with study procedures. 4. Signed and dated informed consent. Exclusion Criteria Both Subjects and care providers 1\. Has dementia, altered mental status, or any psychiatric or co-morbid condition prohibiting the understanding or rending of informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Novant Health Cancer Institute Radiation Oncology

    Wilmington, North Carolina, 28401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.